Daste, Amaury <br/><br/>
Immunotherapy in head and neck cancer: Need for a new strategy? Rapid progression with nivolumab then unexpected response with next treatment.  [electronic resource] 

 -  Oral oncology  01 2017 
 - e1-e3 p.  digital 
<br/><br/> Publication Type: Case Reports; Letter 
<br/><br/><label>ISSN: </label>1879-0593 
<br/><br/><label>Standard No.: </label>10.1016/j.oraloncology.2016.10.020  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--therapeutic use<br/>Antineoplastic Agents--therapeutic use<br/>Carcinoma, Squamous Cell--pathology<br/>Disease Progression<br/>Head and Neck Neoplasms--pathology<br/>Humans<br/>Immunotherapy<br/>Male<br/>Middle Aged<br/>Nivolumab<br/>Squamous Cell Carcinoma of Head and Neck